ArticleFrontiers in genetics2021
Identification of IGF2BP3 as an Adverse Prognostic Biomarker of Gliomas.
Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- IGF2BP3 promotes gastric cancer progression by inhibiting ferroptosis through ETV4-mediated regulation of GCH1.Cancer biology & therapy · 2026Article
- Establishment of an alternative splicing prognostic risk model and identification of FN1 as a potential biomarker in glioblastoma multiforme.Scientific reports · 2025Article
- The emerging roles of aberrant alternative splicing in glioma.Cell death discovery · 2025Review
- Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment.Frontiers in immunology · 2025Article
- Unveiling the significance of cancer-testis antigens and their implications for immunotherapy in glioma.Discover oncology · 2024Review
- Article
- Interplay of RNA mBiomedicines · 2024Article
- Emerging Roles and Mechanisms of RNA Modifications in Neurodegenerative Diseases and Glioma.Cells · 2024Review
- mCancers · 2024Review
- Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches.Frontiers in pharmacology · 2024Review
- Effects of RNA methylation on Tumor angiogenesis and cancer progression.Molecular cancer · 2023Review
- Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma.Cell death & disease · 2023Article
- NTranslational cancer research · 2023Article
- Review
- RNA mMolecular oncology · 2023Review
- The paralogues MAGOH and MAGOHB are oncogenic factors in high-grade gliomas and safeguard the splicing of cell division and cell cycle genes.RNA biology · 2023Article
- Research Progress on the Role of RNA m6A Modification in Glial Cells in the Regulation of Neurological Diseases.Biomolecules · 2022Review
- A Novel Splice Variant ofCancers · 2022Article
- IMP3 promotes re-endothelialization after arterial injury via increasing stability of VEGF mRNAhv.Journal of cellular and molecular medicine · 2022Article
- The role and regulatory mechanism of mFrontiers in genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyladenosine (m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.